These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29182146)

  • 1. Immunoproteasome functions explained by divergence in cleavage specificity and regulation.
    Winter MB; La Greca F; Arastu-Kapur S; Caiazza F; Cimermancic P; Buchholz TJ; Anderl JL; Ravalin M; Bohn MF; Sali A; O'Donoghue AJ; Craik CS
    Elife; 2017 Nov; 6():. PubMed ID: 29182146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome.
    Diez-Rivero CM; Lafuente EM; Reche PA
    BMC Bioinformatics; 2010 Sep; 11():479. PubMed ID: 20863374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10.
    Schmidtke G; Schregle R; Alvarez G; Huber EM; Groettrup M
    Mol Immunol; 2019 Sep; 113():22-30. PubMed ID: 29208314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis.
    Schmidt C; Berger T; Groettrup M; Basler M
    Front Immunol; 2018; 9():2386. PubMed ID: 30416500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subunit specific inhibitors of proteasomes and their potential for immunomodulation.
    Kisselev AF; Groettrup M
    Curr Opin Chem Biol; 2014 Dec; 23():16-22. PubMed ID: 25217863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunoproteasome: a novel drug target for autoimmune diseases.
    Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCPS: A Web Server to Predict Proteasomal Cleavage Sites.
    Gomez-Perosanz M; Ras-Carmona A; Reche PA
    Methods Mol Biol; 2020; 2131():399-406. PubMed ID: 32162269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation.
    Mishto M; Liepe J; Textoris-Taube K; Keller C; Henklein P; Weberruß M; Dahlmann B; Enenkel C; Voigt A; Kuckelkorn U; Stumpf MP; Kloetzel PM
    Eur J Immunol; 2014 Dec; 44(12):3508-21. PubMed ID: 25231383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome.
    Cui H; Baur R; Le Chapelain C; Dubiella C; Heinemeyer W; Huber EM; Groll M
    Chembiochem; 2017 Mar; 18(6):523-526. PubMed ID: 28098422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the Role of the Immunoproteasome in Protein Homeostasis.
    Basler M; Groettrup M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunoproteasome in antigen processing and other immunological functions.
    Basler M; Kirk CJ; Groettrup M
    Curr Opin Immunol; 2013 Feb; 25(1):74-80. PubMed ID: 23219269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the processing of seven human tumor antigens by intermediate proteasomes.
    Guillaume B; Stroobant V; Bousquet-Dubouch MP; Colau D; Chapiro J; Parmentier N; Dalet A; Van den Eynde BJ
    J Immunol; 2012 Oct; 189(7):3538-47. PubMed ID: 22925930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability.
    Ladi E; Everett C; Stivala CE; Daniels BE; Durk MR; Harris SF; Huestis MP; Purkey HE; Staben ST; Augustin M; Blaesse M; Steinbacher S; Eidenschenk C; Pappu R; Siu M
    J Med Chem; 2019 Aug; 62(15):7032-7041. PubMed ID: 31283222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity.
    Huber EM; Basler M; Schwab R; Heinemeyer W; Kirk CJ; Groettrup M; Groll M
    Cell; 2012 Feb; 148(4):727-38. PubMed ID: 22341445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification and separation of the 20S immunoproteasome from the constitutive proteasome and identification of the subunits by LC-MS.
    Dechavanne V; Vilbois F; Glez L; Antonsson B
    Protein Expr Purif; 2013 Feb; 87(2):100-10. PubMed ID: 23147206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
    Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
    Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of proteasomal cleavage probabilities from kinetic analysis of time-dependent product formation.
    Peters B; Janek K; Kuckelkorn U; Holzhütter HG
    J Mol Biol; 2002 May; 318(3):847-62. PubMed ID: 12054828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting immunoproteasome in neurodegeneration: A glance to the future.
    Tundo GR; Cascio P; Milardi D; Santoro AM; Graziani G; Lacal PM; Bocedi A; Oddone F; Parravano M; Coletta A; Coletta M; Sbardella D
    Pharmacol Ther; 2023 Jan; 241():108329. PubMed ID: 36526014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.
    Guillaume B; Chapiro J; Stroobant V; Colau D; Van Holle B; Parvizi G; Bousquet-Dubouch MP; Théate I; Parmentier N; Van den Eynde BJ
    Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18599-604. PubMed ID: 20937868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune and non-immune functions of the immunoproteasome.
    Angeles A; Fung G; Luo H
    Front Biosci (Landmark Ed); 2012 Jan; 17(5):1904-16. PubMed ID: 22201844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.